CDX2 confers ferroptosis resistance in stage II-III colon cancer via upregulation of NUPR1

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A cancer J clinicians. 2021;71:209–49.

Google Scholar 

Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: J Eur Soc Med Oncol. 2013;24:vi64–72.

Google Scholar 

O’Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol: J Am Soc Clin Oncol. 2011;29:3381–8.

Google Scholar 

Beck F, Chawengsaksophak K, Waring P, Playford RJ, Furness JB. Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. Proc Natl Acad Sci USA. 1999;96:7318–23.

Google Scholar 

Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:4665–73.

Google Scholar 

Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. Am J Surg Pathol. 2013;37:1532–41.

Google Scholar 

Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci USA. 2012;109:E3196–3205.

Google Scholar 

Coebergh van den Braak RR, Martens JW, Ijzermans JN. CDX2 as a Prognostic Biomarker in Colon Cancer. N Engl J Med. 2016;374:2182.

Google Scholar 

Stockwell BR, Friedmann Angeli JP, Bayir H, et al. A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171:273–85.

Google Scholar 

Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82.

Google Scholar 

Conrad M, Lorenz SM, Proneth B. Targeting Ferroptosis: New Hope for As-Yet-Incurable Diseases. Trends Mol Med. 2021;27:113–22.

Google Scholar 

Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem Biol. 2019;26:623–33.e629.

Google Scholar 

Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Sci (N Y, NY). 2020;368:85–9.

Google Scholar 

Gao W, Wang X, Zhou Y, Wang X & Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Sig Transduct Target Ther. 2022;7:196.

Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol cancer. 2022;21:47.

Google Scholar 

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021;43:102006.

Google Scholar 

Mallo GV, Fiedler F, Calvo EL, Ortiz EM, Vasseur S, Keim V, et al. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem. 1997;272:32360–9.

Google Scholar 

Narzt MS, Nagelreiter IM, Oskolkova O, Bochkov VN, Latreille J, Fedorova M, et al. A novel role for NUPR1 in the keratinocyte stress response to UV oxidized phospholipids. Redox Biol. 2019;20:467–82.

Google Scholar 

Hamidi T, Cano CE, Grasso D, Garcia MN, Sandi MJ, Calvo EL, et al. Nupr1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. Clin Cancer Res: J Am Assoc Cancer Res. 2012;18:5234–46.

Google Scholar 

Palam LR, Gore J, Craven KE, Wilson JL, Korc M. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma. Cell Death Dis. 2015;6:e1913.

Google Scholar 

Santofimia-Castaño P, Lan W, Bintz J, Gayet O, Carrier A, Lomberk G, et al. Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis. Sci Rep. 2018;8:16999.

Google Scholar 

Lan W, Santofimia-Casta¤o P, Swayden M, Xia Y, Zhou Z, Audebert S. et al. ZZW-115-dependent inhibition of NUPR1 nucleartranslocation sensitizes cancer cells to genotoxic agents. JCI insight. 2020;5:e138117.

Google Scholar 

Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, et al. NUPR1 is a critical repressor of ferroptosis. Nat Commun. 2021;12.647.

Google Scholar 

Jin HO, Seo SK, Woo SH, Choe TB, Hong SI, Kim JI, et al. Nuclear protein 1 induced by ATF4 in response to various stressors acts as a positive regulator on the transcriptional activation of ATF4. IUBMB life. 2009;61:1153–8.

Google Scholar 

Veerla S, Panagopoulos I, Jin Y, Lindgren D, Höglund M. Promoter analysis of epigenetically controlled genes in bladder cancer. Genes, Chromosomes Cancer. 2008;47:368–78.

Google Scholar 

Neira JL, Rizzuti B, Jim‚nez-Alesanco A, Palomino-Sch„tzlein M, Abi n O, Vel zquez-Campoy A. et al. A Phosphorylation-Induced Switch in the Nuclear Localization Sequence of the Intrinsically Disordered NUPR1 Hampers Binding to Importin. Biomolecules. 2020;10:1313.

Google Scholar 

Yu J, Liu D, Sun X, Yang K, Yao J, Cheng C, et al. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/beta-catenin signaling via transactivation of GSK-3beta and Axin2 expression. Cell Death Dis. 2019;10:26.

Google Scholar 

Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019;10:193.

Google Scholar 

Rodriguez R, Schreiber SL, Conrad M. Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Mol Cell. 2022;82:728–40.

Google Scholar 

Feng H, Stockwell BR. Unsolved mysteries: How does lipid peroxidation cause ferroptosis?. PLoS Biol. 2018;16:e2006203.

Google Scholar 

Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, et al. of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, Clinical cancer research : an official journal of the American Association for. Cancer Res. 2020;26:1372–84.

Google Scholar 

Hansen TF, Kjær-Frifeldt S, Eriksen AC, Lindebjerg J, Jensen LH, Sørensen FB, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer. 2018;119:1367–73.

Google Scholar 

SH den Uil, M de Wit, RJC Slebos, PM Delis-van Diemen, J Sanders, SR Piersma, et al. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer. Eur J Cancer. 2021;144:91–100.

Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, et al. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin colorectal cancer. 2017;16:124–8.

Google Scholar 

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, et al. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol. 2018;12:1639–55.

Google Scholar 

Yuan J, Yin Z, Tao K, Wang G, Gao J. Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis. Oncotarget. 2017;8:89160–72.

Google Scholar 

Hestetun KE, Aasebø K, Rosenlund NB, Müller Y, Dahl O, Myklebust MP. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer. Mod Pathol : Off J U S Can Acad Pathol Inc. 2021;34:161–70.

Google Scholar 

Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, et al. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol: Off J U S Can Acad Pathol Inc. 2019;32:1217–31.

Google Scholar 

Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45–64.

Google Scholar 

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35:S78–s103.

Google Scholar 

Hassannia B, Vandenabeele P. T. Vanden Berghe, Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 2019;35:830–49.

Google Scholar 

Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127–36.

Google Scholar 

Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917–21.

Google Scholar 

Chi Y, Remsik J, Kiseliovas V, Derderian C, Sener U, Alghader M, et al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Sci (NY). 2020;369:276–82.

Google Scholar 

Hinoi T, Gesina G, Akyol A, Kuick R, Hanash S, Giordano TJ, et al. CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. Gastroenterology. 2005;128:946–61.

Google Scholar 

Passe CM, Cooper G, Quirk CC. The murine p8 gene promoter is activated by activating transcription factor 4 (ATF4) in the gonadotrope-derived LbetaT2 cell line. Endocrine. 2006;30:81–91.

Google Scholar 

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8( + ) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–4.

Google Scholar 

Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453–7.

Google Scholar 

Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky DJ, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16:2069–83.

Dai E, Han L, Liu J, Xie Y, Zeh HJ, Kang R, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway. Nat Commun. 2020;11:6339.

Google Scholar 

Yu J, Li S, Xu Z, Guo J, Li X, Wu Y, et al. CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and β-catenin stabilisation via transactivation of PTEN expression. Br J Cancer. 2021;124:270–80.

Google Scholar 

Yu J, Liu D, Sun X, Yang K, Yao J, Cheng C, et al. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression. Cell Death Dis. 2019;10:26.

Google Scholar 

Guo RJ, Funakoshi S, Lee HH, Kong J, Lynch JP. The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis. 2010;31:159–66.

Google Scholar 

Guo RJ, Huang E, Ezaki T, Patel N, Sinclair K, Wu J, et al. Cdx1 inhibits human colon cancer cell proliferation by reducing beta-catenin/T-cell factor transcriptional activity, The. J Biol Chem. 2004;279:36865–75.

Google Scholar 

Tamagawa Y, Ishimura N, Uno G, Aimi M, Oshima N, Yuki T, et al. Bile acids induce Delta-like 1 expression via Cdx2-dependent pathway in the development of Barrett’s esophagus. Lab Investig; a J Tech methods Pathol. 2016;96:325–37.

Google Scholar 

Kim HJ, Seo EH, Bae DH, Haam K, Jang HR, Park JL, et al. Methylation of the CDX2 promoter in Helicobacter pylori-infected gastric mucosa increases with age and its rapid demethylation in gastric tumors is associated with upregulated gene expression. Carcinogenesis. 2020;41:1341–52.

Google Scholar 

Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, et al. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nat Commun. 2020;11:3021.

Google Scholar 

Renouf B, Soret C, Saandi T, Delalande F, Martin E, Vanier M, et al. Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells. Nucleic acids Res. 2012;40:3456–69.

Google Scholar 

Coskun M, Troelsen JT, Nielsen OH. The role of CDX2 in intestinal homeostasis and inflammation. Biochimica et biophysica acta. 2011;1812:283–9.

Google Scholar 

Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Eucker J, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF(V600E)-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol: J Am Soc Clin Oncol. 2023;41:4143–53.

Google Scholar